Pfizer (PFE) has been relying on its newly launched and newly acquired products to improve its sales performance amid a decline in revenues from its COVID-19 products.Pfizer records direct sales and alliance revenues from its partner, BioNTech (BNTX) , for the COVID-19 vaccine, Comirnaty, and product revenues from its oral antiviral pill for COVID, Paxlovid. However, revenues from its COVID products are declining due to a demand slump.Nonetheless, Pfizer expects better non-COVID operational revenue growth i ...

Pfizer (PFE) announced that a phase III study evaluating its new respiratory syncytial virus (RSV) Abrysvo in adults aged 18 to 59 met its primary endpoints.Abrysvo was launched to help protect older adults as well as infants through maternal immunization in the United States as well as in the EU in 2023.The study called MONeT evaluated the immunogenicity and safety of Abrysvo versus placebo in adults aged 18 to 59 who are at an increased risk of developing severe RSV-associated lower respiratory tract dise ...

Is this top healthcare stock a good buy for the long run?Pfizer (PFE 0.75%) stock has been struggling for a while now. In the past 12 months, it has declined by 36%. A lack of growth recently, a dependence on acquisitions, and many question marks have resulted in a lot of investors simply taking a pass on this top healthcare stock.But could that be a mistake, and could Pfizer return to glory in 10 years and prove to be a great buy again? Here's where the business may be a decade from now, and whether invest ...

ToplineA late-stage trial of Pfizer’s RSV vaccine showed promising results in adults under 60 years old, suggesting the shot could help people as young as 18, the company announced Tuesday, amid an effort to expand the vaccine’s availability to more people who are at a higher risk to the potentially lethal infection.Pfizer said the shot—approved for adults age 60 and older—had similar effects in adults over age 18. ... [+] Getty Images Key FactsPfizer’s vaccine, marketed as Abrysvo, resulted in an immune re ...

Pfizer Inc (NYSE PFE) stock is up 1.7% at $27.04 at last check, following news a late-stage trial of its respiratory syncytial virus (RSV) vaccine Abrysvo generated an immune response in higher risk adults under the age of 60. The company plans to seek expanded approval of the vaccine for ages 18 to 59.Shares are still struggling with resistance at the $29 level, which has been in place since January and rejected a mid-March rally off 11-year lows. In the last 12 months, PFE shed 35.3%.Short-term options tr ...

A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, the company said Tuesday.The initial data suggests that Pfizer's shot, known as Abrysvo, could help protect a far wider population from RSV. The jab is currently approved in the U.S., Europe, Japan and other countries for adults ages 60 and older and expectant mothers who can pass on protection to their fetuses. But the ...

The current status of this stock might seem bleak. But like a chess grandmaster, Griffin is looking several moves ahead.If there were a hedge fund manager hall of fame, Ken Griffin would be a no-brainer inductee. His skillful leadership of Citadel made it one of the most successful hedge funds ever. It also made Griffin one of the wealthiest people in the world, with a net worth of nearly $37 billion. Understandably, many investors pay close attention to the stocks Griffin buys and sells. Are income investo ...

Pfizer (PFE) ended the recent trading session at $26.58, demonstrating a -0.3% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.04% for the day. Elsewhere, the Dow lost 0.03%, while the tech-heavy Nasdaq added 0.03%.The drugmaker's stock has dropped by 2.06% in the past month, falling short of the Medical sector's loss of 0.6% and the S&P 500's gain of 2.57%.The investment community will be paying close attention to the earnings performance of P ...

There could be a light at the end of the tunnel for this beaten-down stock.Two adages capture the dilemma investors face when they consider buying a beaten-down stock:"Don't try to catch a falling knife.""Buy the dip."These well-known sayings seem to be contradictory. However, they're not when taken in the correct context. Some sinking stocks have poor underlying businesses and should be avoided -- just like a falling knife. Others have solid underlying businesses and are likely to rebound over time.I think ...

Key PointsThe overall market (SPY) surged by nearly 10% in the first quarter, led by the semiconductor sector's 28% gains amid continued AI optimism.Near the end of Q1, a shift toward more defensive sectors, like Utilities, Financials, Industrials, and Consumer Staples, began to take place.With this shift occurring, dividend aristocrats like Pfizer (PFE), Altria Group (MO), Ford (F), and AT&T (T) offer stability and income, positioned at fair values or discounts for investors seeking reliable income streams ...